Publications by authors named "Tim Gunn"
Article Synopsis
- The study assessed how Indigenous Māori individuals experienced open-source automated insulin delivery (AID) systems for managing type 1 diabetes, highlighting issues of health equity.
- Participants reported benefits such as greater empowerment, improved quality of life, and easier glucose control, despite facing challenges related to access and support.
- Structural and socio-economic barriers were identified that hinder equitable use of diabetes technologies for Māori, suggesting the need for strength-based solutions in healthcare redesign.
To assess long-term efficacy and safety of open-source automated insulin delivery (AID) in children and adults (7-70 years) with type 1 diabetes. Both arms of a 24-week randomized controlled trial comparing open-source AID (OpenAPS algorithm within a modified version of AndroidAPS, preproduction DANA-i™ insulin pump, Dexcom G6 continuous glucose monitor) with sensor-augmented pump therapy (SAPT), entered a 24-week continuation phase where the SAPT arm (termed SAPT-AID) crossed over to join the open-source AID arm (termed AID-AID). Most participants (69/94) used a preproduction YpsoPump insulin pump during the continuation phase.
View Article and Find Full Text PDFBackground: Open-source automated insulin delivery (AID) systems are used by many patients with type 1 diabetes. Data are needed on the efficacy and safety of an open-source AID system.
Methods: In this multicenter, open-label, randomized, controlled trial, we assigned patients with type 1 diabetes in a 1:1 ratio to use an open-source AID system or a sensor-augmented insulin pump (control).